TOP TEN perturbations for 39231_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39231_at
Selected probe(set): 204258_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39231_at (204258_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):4.642434Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-4.35363Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):4.186467Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-4.0606337Number of Samples:2 / 4
Experimental | R547 study 1 (24h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.8203564Number of Samples:4 / 4
Experimental | R547 study 1 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.5018215Number of Samples:4 / 4
Experimental | R547 study 3 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
cell cycle inhibition study 1 / untreated A2780 ovarian carcinoma cell sample
Relative Expression (log2-ratio):-2.853756Number of Samples:3 / 3
Experimental | cell cycle inhibition study 1 |
Human ovarian carcinoma cells (A2780) exposed to 3 micromolar of a cell cycle inhibitor for 6hrs. | |
Control | untreated A2780 ovarian carcinoma cell sample |
Untreated human ovarian carcinoma cells (A2780). |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.8157158Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.7869978Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.5803728Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H9N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |